IN THIS ISSUE
Tripp Haston reports on the recent decision by the U.S. Supreme Court which held that the failure of a pharmaceutical manufacturer to disclose even statistically insignificant adverse event reports could serve as a basis for a securities fraud claim.
To read the complete newsletter, click Matrixx Initiatives v. Siracusano The Legal Significance of Insignificant Adverse Event Reports.
Reprinted with permission from the International Association of Defense Counsel and the Drug, Device and Biotechnology Committee. All rights reserved.